Pfenex Inc. (PFNX)
Stock Price:
$12.83 USD
5.17 (67.49%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
440.03M |
| Revenue (ttm) |
41.12M |
| Net Income (ttm) |
-8.13M |
| Shares Out |
34.30M |
| EPS (ttm) |
-0.18 |
| PE Ratio |
n/a |
| Forward PE |
42.37 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$12.83 |
| Previous Close |
$7.66 |
| Change ($) |
5.17 |
| Change (%) |
67.49% |
| Day's Open |
12.65 |
| Day's Range |
12.50 - 13.38 |
| Day's Volume |
12,836,219 |
| 52-Week Range |
5.26 - 14.00 |
More Stats
| Market Cap |
440.03M |
| Enterprise Value |
382.12M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.30M |
| Float |
34.15M |
| EPS (basic) |
-0.22 |
| EPS (diluted) |
-0.18 |
| FCF / Share |
-0.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.44M |
| Short Ratio |
4.26 |
| Short % of Float |
4.92% |
| Beta |
0.86 |
| PE Ratio |
n/a |
| Forward PE |
42.37 |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.70 |
| PB Ratio |
3.43 |
| Revenue |
41.12M |
| Operating Income |
-8.28M |
| Net Income |
-8.13M |
| Free Cash Flow |
-5.54M |
| Net Cash |
57.91M |
| Net Cash / Share |
1.69 |
| Gross Margin |
110.50% |
| Operating Margin |
-20.13% |
| Profit Margin |
-21.10% |
| FCF Margin |
-13.47% |
| ROA |
-4.95% |
| ROE |
-9.22% |
| ROIC |
-59.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.40*
(35.62% upside)
Low
13.0
Current: $12.83
High
20.0
Target: 17.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 50.33 | 14.86 | 28.78 | 60.19 | 9.58 | 10.64 | 11.91 | 11.29 |
| Revenue Growth | 238.74% | -48.38% | -52.19% | 528.13% | -9.97% | -10.66% | 5.49% | - |
| Gross Profit | 45.44 | 9.84 | 23.62 | 54.88 | 4.94 | 3.41 | 5.49 | 4.04 |
| Operating Income | 0.82 | -39.85 | -25.98 | 5.12 | -27.84 | -9.72 | -6.70 | -4.63 |
| Net Income | 1.06 | -39.59 | -25.68 | 5.48 | -28.22 | -9.79 | -4.06 | -2.59 |
| Shares Outstanding | 31.60 | 28.34 | 23.50 | 23.39 | 22.38 | 9.44 | 1.53 | 1.47 |
| Earnings Per Share | 0.03 | -1.40 | -1.09 | 0.23 | -1.26 | -1.04 | -3.76 | -2.84 |
| Operating Cash Flow | -4.13 | -39.43 | -21.51 | -22.27 | 24.23 | -10.00 | -4.60 | -2.89 |
| Capital Expenditures | -0.85 | -1.47 | -2.20 | -2.86 | -1.47 | -0.32 | -0.11 | -0.32 |
| Free Cash Flow | -4.97 | -40.90 | -23.71 | -25.13 | 22.76 | -10.32 | -4.71 | -3.21 |
| Cash & Equivalents | 55.82 | 56.42 | 57.86 | 81.50 | 110 | 49.68 | 9.23 | 11.47 |
| Total Debt | 3.85 | 0.51 | 0.65 | 0.08 | 3.81 | 3.81 | 3.59 | 1.14 |
| Net Cash / Debt | 51.98 | 55.91 | 57.22 | 81.42 | 106 | 45.86 | 5.64 | 10.33 |
| Assets | 84.89 | 81.28 | 79.39 | 103 | 132 | 71.02 | 31.81 | 32.93 |
| Liabilities | 12.59 | 20.14 | 21.63 | 22.98 | 60.51 | 11.15 | 13.08 | 10.29 |
| Book Value | 72.30 | 61.14 | 57.76 | 80.15 | 71.18 | 59.87 | -94.45 | -19.86 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pfenex Inc. |
| Country |
United States |
| Employees |
88 |
| CEO |
Evert B. Schimmelpennink |
Stock Information
| Ticker Symbol |
PFNX |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: PFNX |
| IPO Date |
July 24, 2014 |
Description
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.